drug
Azmiro
Marketedupdated 3mo agoby Slayback Pharma LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 7all catalysts(0)
nothing on the calendar yet
Trials studying Azmiro
- phase2Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
- phase2Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)
- phase2Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
- phase4Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Men
- phase2Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
- phase2Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer
- phase2The COSMYC Trial (COmbined Suppression of MYC)
- phase2COMbination of Bipolar Androgen Therapy and Nivolumab
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 25, 2039
~12.6 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- Mar 25, 2039formulationUS 11311554
- Mar 25, 2039formulationUS 11642355
- Mar 25, 2039formulationUS 12138271
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that